CRPA1A2 NCT07583316 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 28 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 1

Clinical phase

Not yet recruiting

Recruitment status

192

Planned enrollment

2030-03-30

Primary-completion proxy

Executive view

NCT07583316 evaluates CRPA1A2 in Hepatocellular Carcinoma. The disclosed sponsor is Beijing Kerui Biological Technology Co., Ltd., the design is Interventional, and the geographic footprint is China. The first listed primary endpoint is Incidence of dose-limiting toxicities (DLTs) in Part A, assessed over Day 28.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07583316 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Hepatocellular Carcinoma landscape. Drug & Asset MCP drug_fetch was queried for CRPA1A2, while Company & Deal Intelligence MCP organization_fetch was queried for Beijing Kerui Biological Technology Co., Ltd..

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT07583316	CRPA1A2	Phase 1 / Not yet recruiting	Beijing Kerui Biological Technology Co., Ltd.	China	Incidence of dose-limiting toxicities (DLTs) in Part A Day 28	2030-03-30
NCT07644208	IBI-363	Phase 2 / Not yet recruiting	Zhongshan Hospital Fudan University	Geography not reported	Major Pathological Response Rate (MPR) 24 months	2028-06-01
NCT07594964	Leucovorin Calcium	Phase 1 / Recruiting	NeoCura Bio-Medical Technology Co., Ltd.	China	Adverse Event up to 36 months	2029-10-30
NCT07580261	Amifostine	Phase 1 / Not yet recruiting	West China Hospital	China	Occurrence of Dose-Limiting Toxicity (DLT) From first dose to 14 days after the third dose, approximately Day 0…	2028-06-30

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT07583316 is a Phase 1, not yet recruiting study with 192 planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Sequential Assignment.

The primary endpoint is “Incidence of dose-limiting toxicities (DLTs) in Part A” over “Day 28.” The retrieved endpoint description is: Frequency and type of dose-limiting toxicities (DLTs) during the protocol-defined DLT evaluation period in the dose-escalation phase (Part A)..

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 192 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

5 recent result records were selected as contextual evidence for Hepatocellular Carcinoma. These records do not establish direct evidence for NCT07583316 unless the registration number matches.

An Open-label, Multi-center, Phase I/IIa Study of a Personalized Neoantigen DNA Vaccine (GNOS-PV02) and Plasmid Encoded IL-12 (INO-9012) in Combination With Pembrolizumab (MK-3475…

Phase 1/2; n=36; Participants with Grade 1 Treatment-Related Adverse Events = 25 participants Source: https://clinicaltrials.gov/ct2/show/results/NCT04251117

A Phase Ib/II, Open-Label, Multicenter, Randomized Platform Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectab…

Phase 1/2; n=62; Major Pathologic Response (MPR) Rate = 0 percentage of participants (95% Confidence Interval, 0.00 - 11.57); Major Pathologic Response (MPR) Rate = 3.3 percentage of participants (95% Confidence Interval, 0.08 - 17.22) Source: https://clinicaltrials.gov/ct2/show/results/NCT05908786

A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475)…

Phase 3; n=480; Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)(Median): Hazard Ratio (HR) = 0.66(95% CI, 0.51 - 0.84), P-Value = 0.0002; Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)(Median): Hazard Rat… Source: https://clinicaltrials.gov/ct2/show/results/NCT04246177

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

CRPA1A2 is indexed as T cell engagers (TCE) with CD3 x MAGEA1 biology and a global stage of Phase 1. The asset profile lists Beijing Kerui Biological Technology Co., Ltd. as an originator or developer.

Beijing Kerui Biological Technology Co., Ltd. is indexed in China with the website https://corregene.com. The organization record is used to resolve sponsor identity. The record lists 11 development-stage drug assets.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether CRPA1A2 is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT07583316
Protocol source: https://clinicaltrials.gov/study/NCT07583316
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 28 September 2026.

CRPA1A2 in Hepatocellular Carcinoma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Incidence of dose-limiting toxicities (DLTs) in Part A and 2030-03-30 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP